Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome

Ana C. Zamora, Sumedh S. Hoskote, Beatriz Abascal-Bolado, Darin White, Christian W. Cox, Jay H. Ryu, Teng Moua

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Background Interstitial lung disease (ILD) is a common extra-muscular manifestation of antisynthetase (AS) syndrome. ILD prevalence is higher with anti-Jo-1 antibody positivity. Data on long-term outcomes in these patients are lacking. Methods Over 15 years, we identified subjects with anti-Jo-1 positive AS syndrome and ILD. Demographics, pulmonary function testing (PFT), high-resolution computed tomography (HRCT), histopathology, and long-term survival were analyzed. Results We identified 103 subjects (mean age 49.2 years, female predominance [70%]). The predominant myopathy was polymyositis (64%) followed by dermatomyositis (24%). In approximately half of studied subjects, AS syndrome and ILD were diagnosed within 6 months of each other. The majority had restriction on PFTs (98%). Non-specific interstitial pneumonia (NSIP) was the most common HRCT pattern (52%), followed by NSIP overlapping with organizing pneumonia (OP) (22%). Thirty-nine subjects had biopsy data. Ten-year survival was 68%. Multivariable analysis adjusted for age at ILD diagnosis, gender, FVC and DLCO, revealed that male gender (HR = 2.60, p = 0.04) and DLCO at presentation (HR = 0.94, p = 0.05) significantly predicted mortality. Conclusions We present a large cohort of anti-Jo-1 positive AS syndrome with ILD and note good overall survival.

Original languageEnglish (US)
Pages (from-to)39-45
Number of pages7
JournalRespiratory Medicine
StatePublished - Sep 1 2016


  • Antinuclear antibody
  • Antisynthetase syndrome
  • Dermatomyositis
  • Interstitial lung disease
  • Jo-1 antibody
  • Polymyositis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome'. Together they form a unique fingerprint.

Cite this